Conatus Pharmaceuticals Inc (NASDAQ:CNAT) – Analysts at Oppenheimer boosted their FY2022 EPS estimates for shares of Conatus Pharmaceuticals in a research note issued to investors on Wednesday. Oppenheimer analyst J. Olson now expects that the biotechnology company will post earnings of $1.22 per share for the year, up from their prior forecast of $1.16. Oppenheimer has a “Buy” rating and a $16.00 price objective on the stock.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.02. Conatus Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 49.17%. The firm had revenue of $8.80 million during the quarter, compared to the consensus estimate of $9.60 million.
Shares of Conatus Pharmaceuticals (NASDAQ CNAT) traded down $0.32 during trading hours on Monday, reaching $6.92. The company’s stock had a trading volume of 819,589 shares, compared to its average volume of 618,344. The firm has a market cap of $216.74, a PE ratio of -11.28 and a beta of 1.28. The company has a current ratio of 2.82, a quick ratio of 2.82 and a debt-to-equity ratio of 0.47. Conatus Pharmaceuticals has a 52-week low of $3.88 and a 52-week high of $9.40.
A number of large investors have recently made changes to their positions in the business. New York State Common Retirement Fund grew its holdings in Conatus Pharmaceuticals by 156.4% during the 3rd quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 14,700 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Conatus Pharmaceuticals by 77.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,036 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 14,848 shares during the last quarter. Voya Investment Management LLC acquired a new stake in shares of Conatus Pharmaceuticals during the second quarter worth $101,000. Stone Ridge Asset Management LLC acquired a new stake in shares of Conatus Pharmaceuticals during the fourth quarter worth $143,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Conatus Pharmaceuticals by 17.3% during the fourth quarter. Bank of New York Mellon Corp now owns 215,843 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 31,822 shares during the last quarter. Hedge funds and other institutional investors own 39.57% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Oppenheimer Analysts Lift Earnings Estimates for Conatus Pharmaceuticals Inc (CNAT)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3260074/oppenheimer-analysts-lift-earnings-estimates-for-conatus-pharmaceuticals-inc-cnat.html.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.